Acepodia, Inc. (TPEX:6976)

Market Cap	9.47B
Revenue (ttm)	427.00K
Net Income (ttm)	-496.75M
Shares Out	573.68M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,006
Average Volume	479,833
Open	16.60
Previous Close	16.50
Day's Range	16.00 - 16.60
52-Week Range	13.80 - 29.60
Beta	n/a
RSI	38.12
Earnings Date	Mar 26, 2025

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. In addition, the company develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial....

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shih-Chia Hsiao
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6976

Financial Performance

In 2024, Acepodia's revenue was 427,000, a decrease of -97.43% compared to the previous year's 16.59 million. Losses were -496.75 million, -39.22% less than in 2023.